The goal of the CARVYKTI^® REMS is to mitigate the risks of cytokine release syndrome (CRS) and neurological toxicities by:

• Ensuring that Hospitals and their Associated Clinics that dispense CARVYKTI^® are specially certified and have on-site, immediate access to tocilizumab.

• Ensuring those who prescribe, dispense, or administer CARVYKTI^® are aware of how to manage the risks of CRS and neurological toxicities.

Access comprehensive information on Risk Evaluation and Mitigation Strategies for CARVYKTI^®. https://carvyktirems.com